CY1117886T1 - Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα - Google Patents
Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματαInfo
- Publication number
- CY1117886T1 CY1117886T1 CY20161100779T CY161100779T CY1117886T1 CY 1117886 T1 CY1117886 T1 CY 1117886T1 CY 20161100779 T CY20161100779 T CY 20161100779T CY 161100779 T CY161100779 T CY 161100779T CY 1117886 T1 CY1117886 T1 CY 1117886T1
- Authority
- CY
- Cyprus
- Prior art keywords
- naphthalenyl
- pyrazol
- oxy
- ethyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε πολύμορφα και επιδιαλυτώματα του υδροχλωρικού άλατος της 4-[2-[[5-μεθυλ- 1-(2-ναφθαλενυλ)-1Η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολίνης(Ρ027), σε διεργασίες για την παρασκευή τους και σε φαρμακευτικές συνθέσεις που τα περιέχουν.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382025A EP2361904A1 (en) | 2010-02-04 | 2010-02-04 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof |
| EP10382226A EP2426112A1 (en) | 2010-08-09 | 2010-08-09 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| PCT/EP2011/051630 WO2011095579A1 (en) | 2010-02-04 | 2011-02-04 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| EP11702056.0A EP2531177B8 (en) | 2010-02-04 | 2011-02-04 | 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117886T1 true CY1117886T1 (el) | 2017-05-17 |
Family
ID=43897079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100779T CY1117886T1 (el) | 2010-02-04 | 2016-08-08 | Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9051275B2 (el) |
| EP (1) | EP2531177B8 (el) |
| JP (1) | JP5894086B2 (el) |
| KR (2) | KR20120123532A (el) |
| CN (1) | CN102753155B (el) |
| AR (1) | AR080133A1 (el) |
| AU (1) | AU2011212476B2 (el) |
| BR (1) | BR112012018958A8 (el) |
| CA (1) | CA2788024C (el) |
| CO (1) | CO6592093A2 (el) |
| CY (1) | CY1117886T1 (el) |
| DK (1) | DK2531177T3 (el) |
| EC (1) | ECSP12012039A (el) |
| ES (1) | ES2586212T3 (el) |
| HR (1) | HRP20160937T1 (el) |
| HU (1) | HUE029738T2 (el) |
| IL (1) | IL221277A (el) |
| MA (1) | MA34047B1 (el) |
| ME (1) | ME02483B (el) |
| MX (1) | MX339193B (el) |
| NZ (1) | NZ601316A (el) |
| PL (1) | PL2531177T3 (el) |
| PT (1) | PT2531177T (el) |
| RS (1) | RS55046B1 (el) |
| RU (1) | RU2560150C2 (el) |
| SG (2) | SG10201500832PA (el) |
| SI (1) | SI2531177T1 (el) |
| SM (1) | SMT201600264B (el) |
| TN (1) | TN2012000347A1 (el) |
| TW (1) | TWI568729B (el) |
| WO (1) | WO2011095579A1 (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) * | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2792352A1 (en) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
| CA2933511A1 (en) | 2013-12-17 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations |
| JP2017503765A (ja) | 2013-12-17 | 2017-02-02 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | ガバペンチノイドおよびシグマ受容体の組み合わせ |
| JP7094231B2 (ja) | 2016-06-06 | 2022-07-01 | エスティーブ ファーマシューティカルズ エス エイ | がんにおけるシグマ受容体リガンドの使用 |
| AR109024A1 (es) | 2016-07-12 | 2018-10-17 | Esteve Labor Dr | Uso de ligandos del receptor sigma en el dolor post-herpético |
| WO2018059420A1 (zh) * | 2016-09-27 | 2018-04-05 | 苏州科睿思制药有限公司 | E52862盐酸盐晶型h及其制备方法 |
| WO2019068771A1 (en) | 2017-10-04 | 2019-04-11 | Esteve Pharmaceuticals, S.A. | USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS |
| JP2022553802A (ja) | 2019-10-31 | 2022-12-26 | エスケープ・バイオ・インコーポレイテッド | Ｓ１ｐ受容体モジュレーターの固体形態 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| CA2576144C (en) | 2004-08-27 | 2012-12-11 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| MX2008011016A (es) * | 2006-03-01 | 2008-09-08 | Esteve Labor Dr | Inhibidores de receptor sigma. |
| US7695199B2 (en) | 2006-07-20 | 2010-04-13 | Finisar Corporation | Optical subassembly having insertable cylindrical sleeve |
| CN101328155B (zh) * | 2007-06-20 | 2010-11-03 | 上海医药工业研究院 | 噁唑烷衍生物及其制备方法和应用 |
| EP2113501A1 (en) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
-
2011
- 2011-02-04 ES ES11702056.0T patent/ES2586212T3/es active Active
- 2011-02-04 PT PT117020560T patent/PT2531177T/pt unknown
- 2011-02-04 EP EP11702056.0A patent/EP2531177B8/en active Active
- 2011-02-04 AU AU2011212476A patent/AU2011212476B2/en not_active Ceased
- 2011-02-04 DK DK11702056.0T patent/DK2531177T3/en active
- 2011-02-04 ME MEP-2016-154A patent/ME02483B/me unknown
- 2011-02-04 KR KR1020127023081A patent/KR20120123532A/ko active Search and Examination
- 2011-02-04 KR KR1020187015725A patent/KR20180063379A/ko not_active Application Discontinuation
- 2011-02-04 JP JP2012551631A patent/JP5894086B2/ja active Active
- 2011-02-04 SG SG10201500832PA patent/SG10201500832PA/en unknown
- 2011-02-04 MX MX2012009018A patent/MX339193B/es active IP Right Grant
- 2011-02-04 WO PCT/EP2011/051630 patent/WO2011095579A1/en active Application Filing
- 2011-02-04 HU HUE11702056A patent/HUE029738T2/en unknown
- 2011-02-04 NZ NZ601316A patent/NZ601316A/en not_active IP Right Cessation
- 2011-02-04 RS RS20160612A patent/RS55046B1/sr unknown
- 2011-02-04 RU RU2012137495/04A patent/RU2560150C2/ru not_active IP Right Cessation
- 2011-02-04 CN CN201180008354.5A patent/CN102753155B/zh active Active
- 2011-02-04 AR ARP110100380A patent/AR080133A1/es unknown
- 2011-02-04 BR BR112012018958A patent/BR112012018958A8/pt not_active Application Discontinuation
- 2011-02-04 CA CA2788024A patent/CA2788024C/en not_active Expired - Fee Related
- 2011-02-04 SG SG2012053724A patent/SG182628A1/en unknown
- 2011-02-04 US US13/577,078 patent/US9051275B2/en not_active Ceased
- 2011-02-04 MA MA35183A patent/MA34047B1/fr unknown
- 2011-02-04 SI SI201130895A patent/SI2531177T1/sl unknown
- 2011-02-04 US US15/616,347 patent/USRE47214E1/en active Active
- 2011-02-04 PL PL11702056.0T patent/PL2531177T3/pl unknown
- 2011-02-08 TW TW100104115A patent/TWI568729B/zh not_active IP Right Cessation
-
2012
- 2012-07-04 TN TNP2012000347A patent/TN2012000347A1/en unknown
- 2012-07-13 EC ECSP12012039 patent/ECSP12012039A/es unknown
- 2012-08-02 IL IL221277A patent/IL221277A/en not_active IP Right Cessation
- 2012-09-04 CO CO12151303A patent/CO6592093A2/es not_active Application Discontinuation
-
2016
- 2016-07-25 HR HRP20160937TT patent/HRP20160937T1/hr unknown
- 2016-08-04 SM SM201600264T patent/SMT201600264B/it unknown
- 2016-08-08 CY CY20161100779T patent/CY1117886T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117886T1 (el) | Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα | |
| CY1122330T1 (el) | Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης | |
| CY1119974T1 (el) | Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
| CY1116871T1 (el) | Παραγωγα πυρρολοτριαζινονης ως αναστολεις των ρι3κ | |
| EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| CY1117524T1 (el) | Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| CY1117962T1 (el) | Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης | |
| UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
| NO20090628L (no) | Pyridizinon derivativater | |
| EA201400833A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| CY1114669T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
| EA201170772A1 (ru) | Органические соединения | |
| CY1111367T1 (el) | Νεα παραγωγα της διοσμετινης, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
| CY1116775T1 (el) | Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης | |
| CY1113409T1 (el) | Αναστολεις ακτ και ρ70 s6 κινασης | |
| CY1117288T1 (el) | Παραγωγα 2-οξο-1-πυρρολιδινυλ ιμιδαζοθειαδιαζολης | |
| EA201071224A1 (ru) | Ингибиторы limk2, композиции, содержащие их, и способы их применения | |
| EA201201676A1 (ru) | Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы | |
| CY1113914T1 (el) | Νεα παραγωγα διυδροϊνδολονων, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις οι οποιες τα περιεχουν | |
| UY34166A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| EA201171414A1 (ru) | Ингибиторы белков семейства iap | |
| CY1119984T1 (el) | Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν |